Microbiology & Diagnostics

Customer Information COVID-19

What your Bruker Microbiology & Diagnostics Team can do for you during the COVID-19 crisis

Thank you

At Bruker, we have been closely following the evolution of the COVID-19 pandemic. We read and learn every day on how healthcare providers are doing all they can to support patients, understand the epidemiology and spread of the virus.

We are very grateful for those extraordinary efforts.

We realize that in this current critical environment, it is crucial your Bruker product is well functioning and supported.

Digital meetings

We’re pleased to provide a solution for virtual face-to-face meetings with your Bruker Microbiology & Diagnostics team. We are all here to listen, support and address your needs.

Your Bruker Microbiology & Diagnostics team can organize a digital meeting with you, be it to give you support in using the Bruker products, or to discuss additional products to improve your functionality. Read more

On-site service of your Bruker Microbiology & Diagnostics systems

Bruker strives to continue service operations as much as possible under the respective framework set by local authorities.

As many regions and countries implemented travel restrictions, that only allow emergency travel, we are forced to reduce our service operations to urgent maintenance and repair visits for

  • equipment that is used in clinical labs or related to the clinical treatment of patients
  • equipment at risk to cause harm to people or any other significant damage, if not maintained in short term.

Bruker commits to pay special attention to your and our employees’ health and safety. Therefore, we aim on servicing your Bruker system under increased safety conditions. Prior to every service visit we kindly ask you to confirm this by signing a letter. Download the letter.

SARS-CoV-2 diagnostics

  • Rapid and specific detection of two independent SARS-CoV-2 targets by the new FluoroType® SARS-CoV-2 plus IVD-CE real-time PCR kit, in less than two hours. Read more
  • In need of recombinant SARS-CoV-2 antigens for developing COVID-19 in vitro diagnostics? Read more

Save precious time

  • When every minute counts for your critical ICU patients, by using the Sepsityper® solution for direct pathogen identification from positive blood culture bottles within 15-20 minutes. Read more

  • For your lab staff, by replacing steel MALDI targets by disposable ones:

Supply of Bruker Microbiology & Diagnostics CARE consumables

We continue production and shipping of the CARE consumables necessary to run your MALDI Biotyper® / IR Biotyper® / AST / molecular diagnostics applications. We do not anticipate interruptions in the short term, but nevertheless we kindly encourage you to fill your stock, as a careful precaution taking into account the currently unpredictable situation with COVID-19. Read more

Take care and stay healthy!

Your Bruker Microbiology & Diagnostics Team

More information


COVID-19 Related Diagnostics

COVID-19 may be accompanied by a secondary bacterial or viral infection in the immunocompromised individual. Rapid diagnosis is critical to determine the correct course of treatment.

Supporting Microbiology Labs

COVID-19 may be accompanied by a secondary bacterial or viral infection, which must also be diagnosed and managed. Bruker's MALDI Biotyper® is already in place at the labs which have served and will continue to support increased demand. These systems can manage high volumes of testing for any secondary bacterial infection.


As well as needing tests for the virus itself, patients who are critically ill with COVID-19 are susceptible to secondary bacterial infections and require appropriate testing and treatment. An additional risk for these vulnerable patients is the development of sepsis.

Antimicrobial susceptibility testing

Although more research is needed to investigate the link between COVID-19, secondary bacterial infections, and mortality rates, it is clear that Antimicrobial Susceptibility Testing (AST) will need to play a vital role in the treatment programs of patients with COVID-19. By quickly establishing the resistance profile of the bacteria, clinicians can provide the most appropriate antibiotics to fight the infection as soon as possible.


TB primarily affects the lungs, so in light of the recent coronavirus pandemic, efforts are being made to understand how TB patients might be affected by co-infection with SARS-CoV-2.


Laboratories already equipped with the HIV / Hepatitis B (HBV) Charge Virale assay from Biocentric, normally used to quantify viral load in patient samples, can switch their operation directly to COVID-19 testing. The test for COVID-19 follows the same protocols as the HIV/HBV viral load test and can be easily switched to be up and running within a day, with no need for additional training or workflow changes and validation.

COVID-19 and fungal co-infections

As the SARS-CoV-2 virus, which causes COVID-19, continues to take hold across the globe, a significant risk to patients is that the primary infection can be complicated by secondary infection which may be bacterial or fungal.